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Antibody-targeted superantigen has been developed into a new strategy to treat many malignant tumors. In this study, for speciﬁc
targeting to gastric cancer cell, superantigen SEB (Staphylococcal Enterotoxin B) was genetically fused to the single-chain variable
fragment of gastric carcinoma-associated antibody MG7(MG7-scFv) that recognizes the MG7 antigen frequently expressed in
gastric cancer cell. The recombinant MG7-scFv/SEB fusion proteins are expressed in E. coli as inclusion bodies, and the puriﬁed
MG7-scFv/SEBretainshighbindingaﬃnitywithgastriccancercellSGC-7901(positiveMG7antigenexpression).Whenincubated
with eﬀector cell—peripheral blood mononuclear cells (PBMCs), MG7-scFv/SEB could eﬀectively inhibit the proliferation and
induce apoptosis of SGC-7901. After being treated with MG7-scFv/SEB, PBMCs remarkably increased the production of Th1
cytokines (IFN-gamma, IL-2), and slightly increased the production of Th2 cytokines (IL-4, IL-10) in vitro. It was observed that
gastric-tumor-bearingratsadministratedwithMG7-scFv/SEBshowedmoreinﬂammatorycellinﬁltration,moresigniﬁcanttumor
inhibition, and longer survival time than those of rats treated with SEB or NS (Normal Saline). The data indicated that MG7-
scFv/SEB fusion protein could speciﬁcally target gastric cancer cell, enhance the activity of T cells and induce tumor cell apoptosis
to exert the antitumor eﬀect on gastric cancer.
1.Introduction
In recent decades, oncologists have made strenuous attempts
to improve the prognosis of gastric cancer patient; however,
due to unresponsiveness to majority of the available thera-
pies, gastriccancerstillranksasoneofthemostfrequentand
lethal cancers [1–3].
Therefore, alternative treatment approaches have been
madetotreatmalignanttumor,suchasmonoclonalantibody
thathasbecomeanewpotentialimmunotoxinforanticancer
therapy [4–7]. Nevertheless, monoclonal antibody has some
deﬁciencies, such as high molecular weight, low penetration
ability, slow clearance in the blood [5, 8–10], and so
forth. These deﬁciencies result in the low tumor-to-blood
biodistribution ratio [11–15]. In addition, patients may
produce human anti-mouse antibody (HAMA) against most
antibodies used for clinical therapy as they are from murine
hybridoma [15, 16]. How can we circumvent these problems
and enhance the antitumor eﬀect of the immunotoxin?
Single-chain variable fragment (scFv), denoted as the fusion
of the immunoglobulin heavy and light chain variable
regions,canpartiallygetridoftheshortcomingsofthewhole
antibody [17]. The scFv that consists of variable heavy-chain
antibody connected to the variable light chain by a ﬂexible
linkeristhesmallestantibodyfragmentthatretainstheentire
antigen-binding region for a particular antibody [18, 19],
and the molecular weight of scFv is only one-sixth of the
whole antibody [20]. Recently, scFv has had possible clinical
utility [18, 21, 22].
The other part of this immunotoxin is the superantigen.
Superantigen is a family of bacterial or viral protein, named
from its ability to polyclonally activate large fractions (2%–
20%) of the T-cell population cells at picomolar concentra-
tions [23, 24]. Its unique feature is that it bypasses antigen-
processing mechanism, speciﬁcally binds to T-cell receptor
variable region beta-chain (TCR-Vβ) segment, and forms a
trimolecular complex along with major histocompatibility
complex class II (MHC-II) [23, 25–27]. This trimolecular2 Journal of Biomedicine and Biotechnology
complex can trigger T cells proliferation and aﬀect cytokines
production (e.g., IFN-γ, TNF-alpha, IL-2, and IL-12) and
strong cytolytic activity [28–30]. This discovery conﬁrms the
eﬀective application of superantigen in tumor immunother-
apy. SEB, a well-characterized 28-kDa exotoxin produced by
some strains of staphylococcus aureus, is one of the most
commonly used exogenous superantigens for tumor therapy
[30–32].
Here, we constructed a fusion protein consisting with
chemically synthesized MG7-scFv against human gastric-
cancer-associated antigen MG7 and superantigen SEB. The
fusion protein was expressed in E. coli [33]. Then the
antigen-binding activity of the fusion protein was deter-
mined by cell-ELISA and the antitumor eﬀect was examined
both in vitro and in vivo. So far as we know, it is the ﬁrst
time to report on a preliminary investigation into the target
antitumor eﬀect of MG7-scFv/SEB fusion protein on gastric
cancer.
2.MaterialsandMethods
2.1. Reagents. The expression vector pET-32a (+) was
purchased from Novagen (Germany). All enzymes were
purchased from TaKaRa (Japan). Anti-SEB rabbit polyclonal
antibody and HRP-labeled goat anti-rabbit were purchased
from Sigma (US). Apoptotic DNA-Ladder kit was purchased
from Roche (Switzerland). Lymphocyte-separating solution
was produced by Shanghai No. 2 Chemical Reagent Factory
(China).
2.2. Cell Lines and Animals. Human gastric adenocarcinoma
SGC-7901 cell line and human normal gastric mucosal cell
line GES-1 were preserved by our Laboratory. PBMCs were
separated from healthy volunteers. Cells were maintained in
RPMI-1640 and supplemented with 10% fetal bovine serum
(FBS), 100U/mL penicillin G, and 100μg/mL streptomycin
at37◦Cinahumidiﬁedatmospherecontaining5%CO2.The
4–6 week old female SD rats were provided by experimental
animal center of Tongji Medical College of Huazhong
University of Science and Technology.
2.3. Construction, Expression, Puriﬁcation, and Identiﬁca-
tion of Recombinant MG7-scFv/SEB. The plasmid pMD-
18T/MG7-scFv-linker, encoding MG7-scFv (against human
gastric-cancer-associated antigen MG7) with 15-residue C-
terminal linker, was chemically synthesized by Sangon
(Shanghai, China). The Plasmid pMD-18T/SEB, encoding
SEB(S407030), was a kind gift from Dr. Gao Shi-tong (Shen-
zhen Center for Disease Control and Prevention, Shenzhen,
China) [34]. The pMD-18T/MG7-scFv-linker was digested
with Nco I and Bgl II; the pMD-18T/SEB was digested with
BamH I and Sal I; the pET-32a (+) was digested with Nco I
and Sal I. These three digested DNA fragments were ligated
and transformed into E. coli BL21 (DE3). The transformed
DE3 was grown in SB (super broth) culture, containing
2% glucose, 0.05% MgSO4, and 100μg/ml ampicillin. When
the culture reached A600 ≈ 0.8, induction was initiated by
addition of 1mM IPTG (isopropyl-L-D-thiogal-actoside).
After incubation at 37◦C for 2–6 hours, the cells were
harvested at 8,000g for 5 minutes at 4◦C. The pellet was
resuspended in 50mM Tris-HCl, 20mM EDTA, 0.5M NaCl,
1% Triton X-100, pH 8.0, and then vortexed, sonicated for
5 minutes, and centrifugated at 10,000g for 10 minutes
at 4◦C. The steps for sonication and centrifugation were
repeated ﬁve times. The inclusion bodies were dissolved
in freshly prepared denaturation buﬀer (8M guanidine
hydrochloride, 0.1M Tris-HCl, 2mM EDTA, 10mg/mL
DTE, pH 8.0), incubated at room temperature for 4 hours,
and then centrifugated at 18,000g for 20 minutes at 4◦C.
The supernatant was puriﬁed by Ni2+-His Bind Resin aﬃnity
chromatography, and the puriﬁed fusion protein was eluted
with 300mM of imidazole. The solution was slowly dialyzed
against renaturation solution I (2M urea, 50mM Tris-HCl,
2mM GSH, and 1mM GSSG) for 24 hours at 4◦C, then
continued dialyzed against renaturation solution II (50mM
T r i s – H C l ,5m ME D T A ,p H8 . 0 )f o r1 0h o u r sa t4 ◦C. Then,
the upstream 158-residue N-terminal fusion sequence was
cleaved from enterokinase recognition sequence DDDDK
by enterokinase. Digested proteins were dialyzed against
10mM Tris-HCl pH 7.5 and then proteins were applied
to a Superdex-75 column (2.6 × 100cm) and eluted in
10mM PBS (pH 7.6) containing 0.15M NaCl. Fractions
containing proteins of interest were collected and dialyzed
against 10mM Tris-HCl pH 7.5. The fusion protein was
conﬁrmed by Western blot, and stored at −70◦C for further
analysis.
2.4. Antigen-Binding Activity. Brieﬂy, SGC-7901 or GES-1
cells were suspended at a concentration of 2 × 105/mL.
100μL of the cell suspension was added to 96-well
microplate, and incubated at 37◦C for 48 hours. After
discarding the medium, the plate was washed three times by
ﬁlling the wells with 200μL PBS, and then ﬁxed with cold
methanol/acetone solution (1:1) for 30 minutes, blocked
with 0.3% H2O2/methanol at 37◦Cf o r3 0m i n u t e s .S e r i a l
diluted concentrations of MG7-scFv/SEB and SEB were
added to the wells, respectively, (NS was added as negative
control) and incubated at 37◦C for 60 minutes. Washed
twice with PBS, the well was then added with rabbit
anti-SEB antibodies, incubated at 37◦C for another 60
minutes. Washed twice again, the well was added with
sheep anti-rabbit secondary antibodies, incubated at 37◦C
for 30 minutes. Each well was added with TMB (3,3 ,5 , 5  -
tetramethylbenzidine) solution, incubated for 30 minutes,
and then added with equal volume of 2M H2SO4, and the
optical density was read at 450nm.
2.5. Eﬀe c to fM G 7 - s c F v / S E Bo nG a s t r i cC a n c e rC e l lP r o l i f e r -
ation In Vitro. MG7 antigen positive-expression SGC-7901
cells were used as target cells. PBMCs were used as eﬀector
cells. SGC-7901 cells were suspended at a concentration of
5×104/mL, and 100μL of the cell suspensions were added
to 96-well microplate. After an overnight incubation, the
cells were co-cultured with PBMCs at eﬀector: target (E:
T) ratios of 10: 1, and treated with various concentrations
(0.01μg/mL, 0.1μg/mL, 1.0μg/ m L ,a n d1 0μg / m L )o fM G 7 -
scFv/SEB or SEB for 48 hours, respectively. Moreover,Journal of Biomedicine and Biotechnology 3
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Figure 1: The schematic diagram of plasmid pET32a(+)/MG7-scFv/SEB. Enterokinase site: DDDDK; the linker: (Gly4Ser)3; His-Tag: six-
histidine amino acid tag.
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Figure 2: Western blot analysis using primary antibody anti-SEB
and HRP-goat anti-rabbit IgG. lane 1: MG7-scFv/SEB protein after
digestionwithenterokinase;lane2:MG7-scFv/SEBbeforedigestion
with enterokinase.
cells were incubated with 1.0μg/mL of MG7-scFv/SEB for
diﬀerent periods of time (0, 6, 12, 24, 48, and 72 hours).
The cell viability after treating with MG7–scFv/SEB or SEB
was measured by cell counting kit-8 (CCK-8) assay. In brief,
CCK-8(10μL)wasaddedtoeachwellofa96-wellmicroplate
containing 100μL of culture medium and incubated at 37◦C
for 2 hours. The absorbance was then measured at 470cnm
using a Bio-Rad 550 spectropho-tometric microplate reader.
Six wells were repeated per group and all experiments were
performed in triplicate.
2.6. Eﬀect of MG7-scFv/SEB on Gastric Cancer Cell Apoptosis.
SGC-7901 cells were incubated in 60mm culture dish with
PBMCs, allowed to adhere overnight, and then treated
with diﬀerent concentrations (0.1μg/mL, 1.0μg/mL, and
10μg/mL) of MG7-scFv/SEB or NS (normal sodium). Each
group of cells was harvested after 24 hours. The cell suspen-
sionwaspelletedbycentrifugationat800gfor5minutesand
resuspended in 400μLl y s i sb u ﬀer, mixed by gentle vortex.
The sample was incubated with proteinase K (10μg/mL)
at 65◦Cf o r1 2 0m i n u t e s ,a n dc e n t r i f u g a t e df o r1 0m i n u t e s
to precipitate DNA. After supernatant removal, DNA pellet
was washed with 750μL 70% ethanol, centrifuged again
to remove trace ethanol, and air dried for 10 minutes at
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Figure 3: Binding aﬃnity assay of MG7-scFv/SEB to MG7 positive
or negative expression cells by cell-ELISA under diﬀerent concen-
trations, same starting concentration 1.0μg, 4 × serial dilution. (a)
BindingassayofMG7-scFv/SEBtoMG7positivecell(gastriccancer
cell SGC-7901) and (b) binding assay of MG7-scFv/SEB to MG7
negative cell (normal human gastric mucosal cell line GES-1).
room temperature. Each test sample was resuspended in the
gel-loading buﬀer, and then 15μL of each sample solution
was loaded to a 1.5% agarose gel and electrophoresed
at 100V for 45 minutes. Ethidium bromide-stained DNA
could be visualized by transillumination with UV light and
photographed.
2.7. Cytokines Release In Vitro. PBMCs were adjusted to 1
× 106/mL. 100μL of the cell suspension was seeded in 96-
well microplate, and incubated at 37◦Cf o r1h o u rt oa d h e r e .
The cells were cocultured with 1.0μg/mL concentrations of
SEB and MG7-scFv/SEB, respectively, (NS used as negative
control). The supernatant was harvested at 12, 24, 36, 48,4 Journal of Biomedicine and Biotechnology
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Figure 4: The eﬀect of MG7-scFv/SEB fusion protein on SGC-
7901 cell proliferation was detected by CCK-8 assay. When co-
cultured with eﬀector cell PBMCs, both SEB and MG7-scFv/SEB
couldeﬀectivelyinhibittheproliferationofSGC-7901cell(P<. 05).
1234M
Figure 5: DNA ladder after treating with MG7-scFv/SEB. Lane 1:
10μg/mL MG7-scFv/SEB group; lane 2: 1.0μg/mL MG7-scFv/SEB
group; lane 3: 0.1μg/mL MG7-scFv/SEB group; lane 4: normal
sodium group.
and 72 hours after incubation. Then, the cytokines (IL-
2, IFN-gamma, IL-4, and IL-10) secreted by PBMCs were
measured using a standard sandwich ELISA technique with
corresponding kits.
2.8. Inhibition Eﬀe c to fM G 7 - s c F v / S E Bo nG a s t r i cC a n c e r
In Vivo. Rats models of gastric cancer were established by
inoculating 1 × 107 SGC-7901 cells into left hind limbs of
rats. After 12 days, the mean diameter of tumor nodule
Table 1:Theinﬁltrationofinﬂammatorycellandnecrosisoftumor
nodule in gastric-cancer-bearing rats after combined therapy with
MG7-scFv/SEB, SEB, or NS.
Groups Tumor
necrosis
1
Inﬁltration of
inﬂammatory
cells inside
the tumors2
Inﬁltration of
inﬂammatory
cells outside
the tumors2
NS −− −
SEB ++ + +
MG7-scFv/SEB ++ ++ +
1Tumor necrosis: −, no necrosis; +, less than 1/3 of the tumor size; ++, 1/3-
2/3 of the tumor size; +++, more than 2/3 of the tumor size.
2Inﬁltration of inﬂammatory cells: −, no inﬁltration; +, minimal inﬁltra-
tion; ++, medium inﬁltration; +++, intense inﬁltration.
was nearly 1.0cm. Sixty tumor-bearing rats were randomly
divided into 3 groups: NS control group, SEB-treated group,
and MG7-scFv/SEB-treated group. Then, rats in MG7-
scFv/SEB group were administrated with 100μg/mL MG7-
scFv/SEB via the vena caudalis, once every other day for 6
times.TheequivalentqualityofSEBorNSwasadministrated
in SEB group or control group, respectively. One-half rats
in each group were sacriﬁced on the 15th day, and the
subcutaneous tumors were isolated and weighed. The other
half of rats in each group were observed for their survival
period.
2.9. Inﬂammatory Cells Inﬁltration and Necrosis of Tumor
Nodule. The tumor nodules were taken from tumor-bearing
rats on the 15th day after the ﬁrst injection. The subcu-
taneous tumor nodules were ﬁxed in 10% formalin, and
embedded in paraﬃn. Sections were observed by hema-
toxylin and eosin (H&E) dyeing. Grading evaluation criteria
were referred to Q Wang (35). Brieﬂy, the evaluation of
tumor necrosis was −, no necrosis; +, less than 1/3 of the
tumor size; ++, 1/3-2/3 of the tumor size; +++, more than
2/3 of the tumor size. The evaluation of the inﬁltration of
inﬂammatory cell both in and around the tumor was −,
no inﬂammatory cell inﬁltration; +, minimal inﬂammatory
cell inﬁltration; ++, medium inﬂammatory cell inﬁltration;
+++, intense inﬂammatory cell inﬁltration.
2.10. Statistical Analysis. All the results are expressed as
mean ± standard error of the mean (SEM). Student’s t-test
or ANOVA was used to analyze the results. P<. 05 was
considered statistically signiﬁcant.
3. Results
3.1. Construction and Expression of MG7-scFv/SEB. The
expression vector pET32a(+)/MG7-scFv/SEB was con-
structedfortheproductionoffusionproteinMG7-scFv/SEB,
in which the superantigen SEB was linked to the C-
terminal of the anti-MG7 scFv via a (Gly4Ser)3 ﬂexible
linker facilitating both correct folding of the MG7-scFv
and SEB (Figure 1). The expression of the fusion protein
MG7-scFv/SEB was conﬁrmed by Western blot analysisJournal of Biomedicine and Biotechnology 5
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Figure 6: Production of cytokines by stimulated PBMCs: (a) IFN-γ production, (b) IL-2 production, (c) IL-4 production, (d) IL-10
production. The productions of IFN-γ a n dI L - 2a r em u c hm o r et h a nt h o s eo fI L - 4a n dI L - 1 0( P<. 05). It indicated that SEB mainly
activates Th1 cell to upregulate cellular immunity; meanwhile, it slightly activates Th2 cell.
using the anti-SEB antibody. As shown in Figure 2,W e s t e r n
blotting analyses revealed that a protein of about 76kDa was
strongly expressed before digestion with enterokinase, and a
protein of about 56kDa was expressed after digestion with
enterokinase.
3.2. Binding Potential of MG7-scFv/SEB to SGC-7901. The
binding potential of MG7-scFv/SEB to SGC-7901 gastric
cancer cells was examined by using cell-ELISA. As shown in
Figure 3(a), the MG7-scFv/SEB fusion protein demonstrated
a high binding capacity to the SGC-7901 cells, whereas
recombinant SEB exhibited very low binding aﬃnity. As
shown in Figure 3(b), both MG7-scFv/SEB fusion protein
and SEB demonstrated a poor binding capacity with control
cell GES-1 (human normal gastric mucosal cell line, negative
expression of MG7 antigen). These ﬁndings indicated that
MG7-scFv/SEB fusion protein can speciﬁcally target MG7-
positive cell with high aﬃnity.
3.3. Antitumor Eﬀe c to fM G 7 - s c F v / S E Bo nG a s t r i cC a n c e rI n
Vitro. As shown in Figure 4, both SEB and MG7-scFv/SEB
could eﬀectively inhibit the proliferation of SGC-7901 cell
which was cocultured with PBMCs, and the inhibitory eﬀect
exhibited a time- and dose-dependent manner (part of data
notshown).Intheabsenceofeﬀectivecell,thefusionprotein
MG7-scFv/SEB had no obvious inhibition eﬀect of SGC-
7901 cell. The data indicated that the antitumor eﬀect of
MG7-scFv/SEB fusion protein is dependent on the function
of PBMC.
The characteristics of DNA ladders indicated inter-
nucleosomal cleavage of DNA during apoptosis. The results
of agarose gel electrophoresis of DNA for the SGC7901
cells showed an overt ladder shaped band in 1.0μg/mL
and 10μg/mL MG7-scFv/SEB-treates group; the ladder-
shaped band became weaker in 0.1μg/mL treated group,
a n dn oD N Al a d d e r sw e r ed e t e c t e di nN St r e a t i n gg r o u p
(Figure 5).6 Journal of Biomedicine and Biotechnology
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Figure 7: Ten gastric-cancer-bearing rats in each group were sub-
cutaneously injected with same number tumor cells and observed
for tumor nodules growth after being administrated with MG7-
scFv/SEB, SEB, or NS. More potent inhibition of tumor growth was
observed in MG7-scFv/SEB-treated group compared with the other
two groups (P<. 05).
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Figure 8: Ten gastric-cancer-bearing rats in each group were
observed for their survival time after being administrated with
M G 7 - s c F v / S E B ,S E B ,o rN S .T h es u r v i v a lt i m e so ft h er a t si n
MG7-scFv/SEB and SEB group were longer than that of NS group
within60-dayobservation(P<. 05).Therewerestatisticdiﬀerences
among the three groups (P<. 05).
AsshowninFigure 6,bothfusionproteinMG7-scFv/SEB
and SEB could dramatically induce the productions of
cytokine IL-2 and IFN-gamma as compared with NS control
group (P<. 01). The production of cytokine IL-4 and IL-
10 were also increased in MG7-scFv/SEB and SEB group
(P<. 05). The data indicated that MG7-scFv/SEB and SEB
would mainly increase the production of Th1 cytokines (IL-
2, IFN-gamma) and slightly upregulate the production of
Th2 cytokines (IL-4, IL-10).
3.4. Antitumor Eﬀect of MG7-scFv/SEB on Gastric Cancer In
Vivo. The eﬀect of MG7-scFv/SEB on SGC-7901 prolifera-
tion in vivo was detected via gastric-cancer-bearing rat. As
shown in Figure 7, the average weights of tumor nodules in
MG7-scFv/SEB- and SEB-treated groups were signiﬁcantly
lighter than that in NS group, suggesting that both SEB
and MG7-scFv/SEB have obviously antitumor eﬀect in vivo,
especially the latter. The results in Figure 8 showed that the
survival times of the rats in MG7-scFv/SEB and SEB groups
werelonger than that of NS group within60-day observation
(P<. 05). These results indicated that MG7-scFv/SEB fusion
protein eﬀectively inhibited gastric cancer growth in vivo.
As shown in Table 1, extensive inﬂammatory cells were
observed in tumor nodules of gastric-cancer-bearing rats
treated with MG7-scFv/SEB; relatively less inﬂammatory
cells were present in the tumors of SEB-treated rats; little
inﬂammatory cells were found inside and around tumors of
NS control group.
4. Discussion
SEB,anexotoxinproducedbysomestrainsofstaphylococcus
aureus, is a bacterial superantigen that has been deeply
studiedintumortherapy[30,31,35].Asasuperantigen,SEB
can polyclonally activate CTL (cytotoxic T lymphocytes),
and massively produce cytokines in vivo [31]. It is capable
of killing tumor cells with similar injuring eﬀect on normal
cells, to some extent, limiting its clinical application. The
application of hybridoma technology and genetic engineer-
ing technology to fuse superantigen with a tumor-speciﬁc
vector to generate a fusion protein that can selectively target
tumor cells can eﬀectively limit these adverse eﬀects. The
antigen of MG7 had high speciﬁcity to gastric cancer, whose
positive rate in gastric cancer was 82.8%–91.2% [36, 37].
For this reason, monoclonal antibody against MG7 has been
recognized as an eﬀective strategy for targeting therapy of
gastric cancer.
In this study, we synthesized scFv against MG7, fused
it with SEB to construct MG7-scFv/SEB fusion protein,
and detected its biological characteristics. Cell-ELISA
results showed that MG7-scFv/SEB fusion protein could
speciﬁcally target MG7-positive gastric cancer cell SGC-
7901 with high aﬃnity, suggesting the correct folding of
fusion protein during the process of renaturation. CCK-8
assay indicated that the fusion protein MG7-scFv/SEB had
signiﬁcant inhibitory eﬀect on SGC7901; nevertheless, there
was no obvious inﬂuence on the cell negative expression
of MG7 antigen. Some further experiments showed that
MG7-scFv/SEB could mainly increase the production of
Th1 cytokines (IL-2, IFN-gamma) and activate cellular
immunity to mediate tumor cell apoptosis and necrosis.
These results indicated that MG7-scFv/SEB was not only
endowed with the speciﬁcity target to the MG7 antigen, but
also maintained the immunogenicity of superantigen SEB.
Given the results we had, SEB was apparently more eﬀective
to produce cytokines and inhibit the proliferation of tumor
cell than MG7-scFv/SEB at the same concentration. We
considered that it was probably due to smaller molecular
weight of SEB than that of MG7-scFv/SEB. But taking
the antigen-speciﬁc antitumor eﬀect into account, MG7-
scFv/SEB is more potential for clinical application than SEB
as the less cytotoxic eﬀect on normal cells.
We used rat as the recipient in tumor xenograft model
because rat has intact immune system which is necessary
for speciﬁcity of SEB. Although the immune system of rat
somehow can reject human tumor cells, the baseline ofJournal of Biomedicine and Biotechnology 7
rejection is same for all groups. So this model still can
tell the diﬀerence between diﬀerent groups even if there is
xenograft rejection. Tumor-bearing rats model experiment
showed that the average weight of tumor nodules in MG7-
scFv/SEB group was signiﬁcantly lighter than those in SEB
or NS group (P<. 05) at the same injection volume. The
survival time of tumor-bearing rats in MG7-scFv/SEB group
was prolonged compared with those in other two groups
(P<. 05). The immunohistochemistry results of tumor
nodule showed that large number of inﬂammatory cells
(neutrophils, lymphocytes, and monocytes) existed inside
and around the tumor nodules in MG7-scFv/SEB-treated
group (P<. 05). The data suggested that MG7-scFv/SEB
couldeﬀectivelyactivateTcelltoinhibitthegrowthofgastric
cancer cell in vivo. Interestingly, the antitumor eﬀect of
MG7-scFv/SEB was signiﬁcantly stronger than that of SEB in
the same dosage. Maybe it was due to the speciﬁcally target
ability to tumor cell of MG7-scFv/SEB.
Taken together, we ﬁnished the construction, expression,
and puriﬁcation of fusion protein MG7-scFv/SEB. The
fusion protein retains high binding aﬃnity to MG7-positive
gastric cancer cell SGC-7901 and the immunogenicity of
SEB. These characteristics ensure that MG7-scFv/SEB can
speciﬁcallykilltumorcellwithoutobvioussideeﬀectonnor-
mal cell. Our data provided a basis for further investigation
of tumor immunotherapy.
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